The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

Inclusion Criteria:

1. Screening laboratory result indicating hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.
2. Chronic HCV infection.
3. HCV treatment-naïve or treatment experienced (interferon [IFN] or pegylated interferon [pegIFN] with or without ribavirin [RBV]; sofosbuvir [SOF] plus RBV with or withoutpegIFN).
4. Non-cirrhotic participants.

Exclusion Criteria:

1. History of severe, life-threatening or other significant sensitivity to any excipientof the study drugs.
2. Female who is pregnant, planning to become pregnant during the study, orbreastfeeding; or male whose partner is pregnant or planning to become pregnant duringthe study.
3. Recent (within 6 months prior to study drug administration) history of drug or alcoholabuse that could preclude adherence to the protocol in the opinion of theinvestigator.
4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) oranti-human immunodeficiency virus antibody (HIV Ab).
5. Co-infection with more than one HCV genotype.